All Stories

  1. The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis
  2. Treatment of MOG antibody associated disorders: results of an international survey
  3. Co-existence of multiple sclerosis and anti-NMDA receptor encephalitis: A case report and review of literature
  4. ‘Is RLS a harbinger and consequence of MS?: Striking results of the ‘RELOMS-T’ study’
  5. Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event
  6. We should monitor our patients with wearable technology instead of neurological examination – No
  7. Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019)
  8. The persistence versus interchangeability of migraine and tension-type headaches in a 5-year population-based validated survey
  9. Management of skin, mucosa and joint involvement of Behçet’s syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet’s syndrome
  10. An open/pilot trial of cognitive behavioral therapy in Turkish patients with refractory chronic migraine
  11. Nervous system involvement in Behçetʼs syndrome
  12. Hemodialysis-related headache and how to prevent it
  13. Age is a critical determinant in recovery from multiple sclerosis relapses
  14. Reduced inhibition in brainstem circuits in classical trigeminal neuralgia
  15. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations
  16. Characteristics of optic neuropathy in Behçet disease
  17. Chronic Migraine: Burden, Comorbidities and Treatment
  18. Behçet’s Syndrome and Nervous System Involvement
  19. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome
  20. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome
  21. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
  22. Undifferentiated headache: broadening the approach to headache in children and adolescents, with supporting evidence from a nationwide school-based cross-sectional survey in Turkey
  23. Anomalies Characteristic of Central Nervous System Demyelination
  24. Common Clinical and Imaging Conditions Misdiagnosed as Multiple Sclerosis
  25. Cervical spinal cord atrophy
  26. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
  27. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
  28. Sex Differences of Migraine: Results of a Nationwide Home-based Study in Turkey
  29. Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation
  30. Neuro-Behçet’s Disease – Clinical Features, Diagnosis and Differential Diagnosis
  31. Determinants of glucose metabolism and the role of NPY in the progression of insulin resistance in chronic migraine
  32. Radiologically isolated syndrome in children
  33. Behçet’s syndrome: providing integrated care
  34. Myelopathy in Behçet's disease: The Bagel Sign
  35. Differences Between General Neurologists and Multiple Sclerosis Specialists in the Management of Multiple Sclerosis Patients: A National Survey
  36. Next generation sequencing analysis of patients with familial cervical artery dissection
  37. Deficient prepulse inhibition of blink reflex in migraine and its relation to allodynia
  38. Identification of 3 Novel Patients with CLCN2-Related Leukoencephalopathy due to CLCN2 Mutations
  39. Headache service quality: evaluation of quality indicators in 14 specialist-care centres
  40. Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders
  41. Integrated multidisciplinary clinics
  42. Infliximab is a plausible alternative for neurologic complications of Behçet disease
  43. Characterization of Migraineurs Having Allodynia
  44. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
  45. Phenotypic features of chronic migraine
  46. The Effects of Dalfampridine on Hereditary Spastic Paraparesis
  47. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome
  48. European headache federation consensus on technical investigation for primary headache disorders
  49. Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey
  50. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
  51. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort
  52. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis
  53. Symptomatic therapy in multiple sclerosis: Big pharma should do more—YES
  54. Retinal nerve fiber layer structure abnormalities in patients with Neuro-Behcet's disease
  55. CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes
  56. Early CNS neurodegeneration in radiologically isolated syndrome
  57. Diagnosis and Treatment in Neurosarcoidosis
  58. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
  59. Population-based study of vestibular symptoms in migraineurs
  60. Case-Based Diagnosis and Management of Headache Disorders
  61. Understanding Multiple Sclerosis Better in 2014 – Environmental Factors, Remyelination, Diagnostic Techniques, Treatment Decisions and the Future Focus of Multiple Sclerosis Treatment
  62. The global burden of headache in children and adolescents – developing a questionnaire and methodology for a global study
  63. Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation
  64. Gender influences headache characteristics with increasing age in migraine patients
  65. Relapses and disability accumulation in progressive multiple sclerosis
  66. Neuro-Behçet Disease and Autoinflammatory Disorders
  67. Moyamoya syndrome or Behçet's disease?
  68. Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis
  69. BAb and MxA as Functional Biomarkers in Routine Clinical Laboratories for the Determination of Anti-IFN-Beta Antibodies and Their Bioactivity Levels in Multiple Sclerosis Patients
  70. The impact of depression and ghrelin on body weight in migraineurs
  71. Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab
  72. Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event
  73. Neuro-Behçet syndrome
  74. A Polysomnographic and Clinical Study of Sleep Disorders in Patients with Behçet and Neuro-Behçet Syndrome
  75. Clinical and Radiological Features in CADASIL and NOTCH3-Negative Patients: A Multicenter Study from Turkey
  76. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations
  77. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
  78. Asymptomatic MS
  79. Management of lower urinary tract dysfunction in multiple sclerosis: A systematic review and Turkish consensus report
  80. Framing education on headache disorders into the Global Burden of Disease Study 2010. The European Headache Federation stands ready
  81. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
  82. Letter by Benbir et al Regarding Article, “The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Scale. A Screening Tool to Select Patients for NOTCH3 Gene Analysis”
  83. The radiologically isolated syndrome dilemma: just an incidental radiological finding or presymptomatic multiple sclerosis?
  84. Impact of sex hormonal changes on tension-type headache and migraine: a cross-sectional population-based survey in 2,600 women
  85. The prevalence of chronic and episodic migraine in children and adolescents
  86. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
  87. Reversible intracranial parenchymal changes in MRI after MCA aneurysm treatment with stent-assisted coiling technique; possible nickel allergy
  88. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study
  89. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort
  90. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis
  91. One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults
  92. Chronic cerebrospinal venous insufficiency: does ultrasound really distinguish multiple sclerosis subjects from healthy controls?
  93. Clinical characteristics of pediatric-onset neuro-Behcet disease
  94. A patient with established primary progressive multiple sclerosis transitions to ‘secondary’ relapsing–remitting disease course following a fulminant demyelinating episode
  95. Evaluation of Parenchymal Neuro-Behçet Disease by Using Susceptibility-Weighted Imaging
  96. Behçet’s Disease
  97. Epidemiological-based childhood headache natural history study: After an interval of six years
  98. Neurofilament ELISA validation
  99. Prevalence Of Multiple Sclerosis In The Metropolitan Area Of Edirne City, Turkey
  100. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease
  101. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis
  102. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis
  103. A Comparative ID Migraine™ Screener Study in Ophthalmology, ENT and Neurology Out-Patient Clinics
  104. EULAR recommendations for the management of Behcet disease
  105. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
  106. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease
  107. Validity of the ID-Migraine screener in the workplace
  108. Immunotherapy for clinically isolated syndrome? Not necessarily...
  109. The Burden of Headache in Neurology Outpatient Clinics in Turkey
  110. The validation of ID migraine™ screener in neurology outpatient clinics in Turkey
  111. Fatigue and sleep disturbance in multiple sclerosis
  112. The R110C mutation in Notch3 causes variable clinical features in two Turkish families with CADASIL syndrome
  113. Economic impact of primary headaches in Turkey: a university hospital based study: part II
  114. The spectrum of multiple sclerosis and treatment decisions
  115. Headache in Behçet's Syndrome
  116. Prevalence and factors affecting headache in Turkish schoolchildren
  117. Cerebral venous thrombosis is associated with major vessel disease in Behcet's syndrome
  118. Validity and Reliability of the Turkish Migraine Disability Assessment (MIDAS) Questionnaire
  119. Beh??et??s syndrome and the nervous system
  120. MRI Findings in Pediatric Neuro-Behçet's Disease
  121. Behçet's Syndrome
  122. Bone status in multiple sclerosis: beyond corticosteroids
  123. A whole genome screen for linkage in Turkish multiple sclerosis
  124. Arthritis during interferon beta-1b treatment in multiple sclerosis
  125. The Sensitivity and Specificity of the Case Definition Criteria in Mersin
  126. Hepatitis B vaccine related-myelitis?*
  127. Vasculitis of the nervous system
  128. Beh�et's disease: diagnostic and prognostic aspects of neurological involvement
  129. Corticosteroid therapy augments gastroduodenal permeability to sucrose
  130. Survival and predictors of disability in Turkish MS patients
  131. Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome
  132. Optic neuritis: A population-based study in Olrnsted County, Minnesota
  133. Glioblastoma of the cerebellum. Computed tomographic and pathologic considerations